An analogue of alpha-MSH
Alpha-melanocyte stimulating hormone is what tells melanocytes to produce pigment. Melanotan II is a cyclic analogue of it, built to be considerably more stable than the natural hormone and to act at several melanocortin receptors.
It was developed at a university programme originally interested in reducing sun exposure by inducing pigmentation without ultraviolet light. The chemistry works; what followed is more complicated.
Closing the peptide into a ring is the durable part of that design. A cyclic structure restricts how the molecule can fold and removes the free ends that peptidases attack first, which is why the analogue persists where the natural hormone does not. Stability was the object of the exercise, and on that narrow measure the exercise succeeded.
Why it acts in more than one place
The melanocortin family has five receptors, and they do very different jobs: pigmentation, appetite, inflammation, sexual function. Melanotan II is not selective between them, which is why its reported effects extend well past the skin.
PT-141 came out of exactly that observation. What is a side effect from a pigmentation standpoint became a separate development programme in its own right.
Anyone asking what is melanotan 2 will be handed the phrase tanning peptide, which is accurate about the intent and misleading about the result. Non-selective activity across a receptor family governing appetite, inflammation and sexual function is not an incidental quirk; it is the predictable consequence of the chemistry. The literature indexed on PubMed is where those observations were recorded.
| Analogue of | Alpha-melanocyte stimulating hormone |
| Structure | Cyclic, non-selective |
| Receptors | Multiple melanocortin subtypes |
| Reported effects | Nausea, flushing, changes to existing moles |
| Regulatory status | Not approved anywhere; warnings issued in several countries |
| Format | Pre-filled peptide pen |
| Related compound | PT-141 |
| Category | Research use only |
Numbers from the laboratory bench, not from a clinic.
What is documented, and what to take seriously
Reported effects include nausea, flushing and changes in the appearance of existing moles. That last one deserves more weight than it usually gets online: any compound that stimulates melanocytes warrants attention to pigmented lesions.
There is no approved melanotan II product anywhere, and regulators in several countries have issued specific warnings about material sold under this name. We supply it as research material and we would rather state that plainly than let the page read as an endorsement.
We are not going to write around the mole point either. A compound that drives melanocyte activity, and a pigmented lesion whose appearance changes, are not two unrelated facts, and the appropriate response to the second is a dermatological assessment rather than a forum thread. That sentence belongs on the page even though it costs us orders.
Buying melanotan 2 when no approved product exists
The absence of any authorised product has a supply consequence worth stating plainly. There is no reference standard, no licensed manufacturer and no regulator inspecting what gets sold under the name, so a batch certificate is the only document standing between a buyer and whatever happens to be in the vial. The signs of a supplier worth avoiding are worth reading before any order in this part of the catalogue.
One melanocortin analogue does hold a European authorisation for a rare condition, and its European assessment report shows what a reviewed dossier in this receptor family looks like: a defined indication, a named population, an assessment anyone can read. Melanotan II has nothing comparable behind it, and national regulators have taken positions on material sold under the name that differ from country to country. If an order crosses a border, what applies when research material enters the EU covers the general framework, and your own jurisdiction settles the specific answer.
For readers who arrived from the dermal side of the catalogue, the instructive comparison is the GHK-Cu file: the same broad research area, a substantially larger published record in skin models, and none of the regulatory history this page has to carry. One area, two compounds, very different documentation behind them.
Melanotan 2 in the catalogue
Purity checked at 99% minimum on every run, paperwork on request.
Where Melanotan 2 fits in
Where to read on, if this was useful.
About Melanotan 2
What readers ask at this point.